Payment overview · 2025
General Payments
$698.96
38 reported records · 10 companies
Healthcare provider profile · identity verified
John C. Bausher, MD, PHD
Allopathic & Osteopathic Physicians|Family Medicine · ABERDEEN, WA · NPI 1033207824
Verified facts
What the public records show
CMS Open Payments records show John C. Bausher, MD, PHD received $698.96 in general payments during 2025 across 38 reported records.
Amgen Inc. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Otezla, Shingrix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $202.04 | 28.9% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $151.42 | 21.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.60 | 9.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.20 | 9.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.76 | 6.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.72 | 6.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $43.64 | 6.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.60 | 5.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.34 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.64 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $698.96 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $202.04 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $179.22 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $144.48 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.20 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.76 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.72 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.76 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $6.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 136 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 72 |
| Lisinopril | Lisinopril | 327 | 75 |
| Metformin Hcl | Metformin Hcl | 218 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 44 |
| Losartan Potassium | Losartan Potassium | 185 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 43 |
| Gabapentin | Gabapentin | 176 | 38 |
| Omeprazole | Omeprazole | 170 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 167 | 36 |
| Furosemide | Furosemide | 160 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 153 | 34 |
| Simvastatin | Simvastatin | 145 | 39 |
| Jardiance | Empagliflozin | 138 | 25 |
| Eliquis | Apixaban | 136 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 11 |
| Alprazolam | Alprazolam | 120 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 28 |
| Trazodone Hcl | Trazodone Hcl | 106 | 29 |
| Glipizide Er | Glipizide | 97 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 31 |
| Potassium Chloride | Potassium Chloride | 94 | 24 |
| Meloxicam | Meloxicam | 93 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 16 |
| Allopurinol | Allopurinol | 83 | 21 |
| Warfarin Sodium | Warfarin Sodium | 81 | 17 |
| Mirtazapine | Mirtazapine | 80 | 11 |
| Trulicity | Dulaglutide | 76 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 26 |
| Donepezil Hcl | Donepezil Hcl | 72 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 65 | 16 |
| Tramadol Hcl | Tramadol Hcl | 61 | 17 |
| Prednisone | Prednisone | 60 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 16 |
| Estradiol | Estradiol | 56 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 13 |
| Spironolactone | Spironolactone | 50 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 13 |
| Carvedilol | Carvedilol | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Atenolol | Atenolol | 43 | 11 |
| Ezetimibe | Ezetimibe | 43 | 18 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 12 |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 11 |
| Ozempic | Semaglutide | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Otezla | Apremilast | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $698.96 · 38 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, ELIQUIS, JARDIANCE, NURTEC ODT, OTEZLA, PAXLOVID, PREVNAR 20, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XIFAXAN, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error